Overview

* Electromed ( ELMD ) Q1 FY 2026 revenue grows 15.1% yr/yr to $16.9 mln

* Net income rises 44.9% to $2.1 mln, reflecting strong operational execution

* Company authorized $10 mln stock repurchase in Q1

Outlook

* Electromed ( ELMD ) expects manufacturing optimization to support future growth

* Company anticipates CRM system to boost sales productivity

* Electromed ( ELMD ) aims for attractive returns in fiscal 2026 and beyond

Result Drivers

* SALES TEAM EXPANSION - Increase in direct sales representatives and higher net revenues per representative drove revenue growth

* HOSPITAL AND DISTRIBUTOR GROWTH - Significant revenue growth in hospital and distributor markets contributed to overall revenue increase

* OPERATIONAL EFFICIENCIES - Improved efficiencies and new CRM system enhanced sales productivity and profitability

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 $16.9

Revenue mln

Q1 EPS $0.25

Q1 Net $2.1 mln

Income

Q1 $2.7 mln

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Electromed Inc ( ELMD ) is $35.50, about 31.8% above its November 10 closing price of $24.20

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)